Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center, discuss findings from this phase III trial of nivolumab combined with ipilimumab in treatment-naive patients with advanced disease (Abstract 9505).
Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000). To see the Italian version of this interview, please click here.
Arjun Vasant Balar, MD, of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses findings on atezolizumab as first-line therapy in cisplatin-ineligible locally advanced/metastatic disease (Abstract LBA4500).
Maria Clemence Schwaederle, PharmD, of the University of California, San Diego, discusses an analysis of 13,203 patients in phase I clinical trials, which showed that a personalized strategy led to improved response rate and progression-free survival (Abstract 11520).
Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, discusses findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in patients with epithelial ovarian cancer (Abstract LBA5503).
Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Davies, MD, PhD, of the University of Texas MD Anderson Cancer Center, discuss this phase III study of dabrafenib plus trametinib vs dabrafenib monotherapy in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma (Abstract 9502).
